Lorazepam-Induced Toxicity in the Aged

Completed · Phase 4

Conditions studied: Anxiety Disorders, Generalized Anxiety Disorder

In brief

This study will compare the effects of an acute dose of lorazepam to a placebo in elderly patients with generalized anxiety disorder (GAD).

Key facts

Study ID

NCT00044642

Run by

Nathan Kline Institute for Psychiatric Research

People needed

90

Starts

2000-12-01

Expected to finish

2007-07-01

Last updated by the study team

2013-12-06

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Lorazepam treatment for at least 3 months
• Cognitively intact
• Note: Individuals who are unable or unwilling to have an MRI may be included

You may not qualify if…

• Major psychiatric disorder other than GAD
• Significant medical illness which may increase the likelihood of adverse reactions to lorazepam
• Severe loss of hearing or vision
• Current or past history of alcohol dependence
• Substance abuse within the past 6 months
• MRI evidence of infection, infarction, or other lesions suggestive of intervening neurological disease
• Clinical symptoms that suggest neurological disease
• Dementia or other mental syndromes or disorders

Where it is running

• NYU/Bellevue General Clinical Research Center (8East) — New York, New York, United States
• Nathan S. Kline Institute — Orangeburg, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.